Summary of Product Characteristics (SmPC) - Bonjela Junior gel
1 NAME OF THE MEDICINAL PRODUCT
Bonjela Junior gel
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Lidocaine hydrochloride 0.5% w/w
Cetylpyridinium chloride 0.025% w/w
Excipients with known effect:
Ethanol 96% 242.2 mg/1g
Fragrances containing allergens (Eugenol)*
*in banana flavour
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oromucosal gel
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the relief of pain from common mouth ulcers and denture irritation.
4.2 Posology and method of administration
Route of Administration: Oromucosal
Adults, the elderly and children over 5 months: Apply a little gel to the sore area with either a clean fingertip or swab. This may be repeated after twenty minutes and then every three hours.
4.3 Contraindications
Hypersensitivity to lidocaine, cetylpyridinium chloride, or to any of the excipients listed in section 6.1.
Known hypersensitivity to local anaesthetics of the amide type.
Babies under 5 months.
In patients who have a history of or are suspected to have methaemoglobinaemia (see section 4.8).
4.4 Special warnings and precautions for use
To be used with caution in patients with hepatic or cardiac dysfunction.
Do not exceed the stated dose. Not recommended for infants under five months.
Keep out of the reach and sight of children. If symptoms persist consult your doctor or dentist.
Excessive dosage, short intervals between doses or use on traumatised mucosa may result in high plasma levels and serious adverse effects (see Section 4.9).
Warnings related to Excipients:
This medicine contains 242.2 mg of alcohol (ethanol) per 1g. The amount in each 1g of this medicine is equivalent to less than 7 ml beer or 3 ml of wine. The small amount of alcohol in this medicine will not have any noticeable effects. It may cause burning sensation on damaged skin.’
This medicine contains less than 1 mmol sodium (23 mg) in each 1g, that is to say essentially ‘sodium-free’.
This medicine contains fragrance with Eugenol. Eugenol may cause allergic reactions.
4.5 Interaction with other medicinal products and other forms of interaction
Concurrent use of either cimetidine or propranolol increases the risk of lidocaine toxicity. Lidocaine is antagonised by those diuretics which cause hypokalaemia.
Lidocaine should be used with caution in patients receiving other local anaesthetics or agents structurally related to amide-type local anaesthetics, e.g. antiarrhythmic drugs such as mexiletine, since the toxic effects may be additive.
While a number of interactions are theoretically possible with lidocaine, these drug interactions are unlikely to be clinically relevant to the use of the product, which is administered topically.
The toxicity of oral lidocaine may be increased when the product is taken in combination with the following drugs:
- Erythromycin
- Itraconazole
- Fluvoxamine
- Beta blockers e.g. propranolol, bisoprolol.
4.6 Fertility, pregnancy and lactation
Pregnancy:
The safety of this medicinal product for use in human pregnancy has not been established. The product is, therefore, not recommended during pregnancy.
Lactation/Breastfeeding:
A small amount of lidocaine enters breast milk, but there are no established data showing harmful effects at therapeutic doses. It is not known if cetylpyridinium chloride excretes into breast milk.
Patients should first consult a healthcare professional before using this product during breastfeeding.
Fertility:
No data on human fertility are available.
4.7 Effects on ability to drive and use machines
None
4.8 Undesirable effects
Adverse reactions have been ranked under headings of frequency using the following convention:
Very common: ≥ 1/10
Common: ≥ 1/100 to < 1/10
Uncommon: ≥ 1/1,000 to < 1/100
Rare: ≥ 1/10,000 to <1/1,000
Very Rare: < 1/10,000
Not known: Frequency unable to be classified from available data.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
| System Organ Class | Preferred Term | Frequency |
| Blood and lymphatic system disorders | Methaemoglobinaemia | Not known |
| Immune System Disorders | Hypersensitivity1 | Not known |
| Skin and subcutaneous tissue disorders | Contact dermatitis | Not known |
Description of Selected Adverse Reactions
1Hypersensitivity reactions may present in the form of angioedema, urticaria, bronchospasms and hypotension with syncope.
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Symptoms
Overdose is highly unlikely given the size of the pack. No experience of overdosage.
It is most unlikely, even with misuse or excessive application of the gel, that the large amounts of lidocaine hydrochloride or cetylpyridinium chloride required to produce clinically-relevant toxic effects would be reached. In the event of overdose, use should be discontinued and a doctor consulted.
The toxic effects of lidocaine are directly related to blood concentrations. Symptoms are dizziness, cyanosis due to methaemoglobinaemia, muscular tremors, convulsions, coma, irregular and weak breathing, cardiac standstill, bronchial spasm, severe hypotension, asystole, bradycardia, apnoea, seizures, coma, cardiac arrest, respiratory arrest, and death.
Management
In the unlikely event of overdose with this product, immediate treatment should be sought which should be symptomatic and supportive.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Lidocaine, combinations; ATC Code: N01BB52
Lidocaine is a local anaesthetic of the amide type, acting to produce reversible loss of sensation by preventing or diminishing the generation and transmission of sensory nerve impulses near the site of application. Depolarisation of the neuronal membrane and ion exchange are reversibly inhibited.
Cetylpyridinium chloride is a quaternary pyridinium antiseptic with actions and uses similar to those of other cationic surfactants.
5.2 Pharmacokinetic properties
Lidocaine is readily absorbed through the mucous membranes and is hydrolysed mainly by the liver.
5.3 Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
6.1 List of excipients
Ethanol 96%
Glycerol
Fragrances containing allergens (Eugenol)*
*in banana flavour
Sodium Saccharin
Carbomer
Triethanolamine
Water
6.2 Incompatibilities
None known.
6.3 Shelf life
Two years
6.4 Special precautions for storage
Do not store above 25°C.
6.5 Nature and contents of container
10g of product is filled into a 16 x 101mm aluminium collapsible tube internally lacquered with a 9mm membrane nozzle with spiked cap.
15g of product is contained in a multi-layered plastic and aluminium tube with silver plastic tamper evident seal and plastic cap. The tube is then packed into a carton.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
Not applicable.
7 MARKETING AUTHORISATION HOLDER
Reckitt Benckiser Healthcare (UK) Ltd, 103-105 Bath Road, Slough, Berkshire, SL1 3UH
8 MARKETING AUTHORISATION NUMBER(S)
PL 00063/0657.
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
22 January 1988 / 04 Feburary 2000
10 DATE OF REVISION OF THE TEXT
17/06/2026